A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2018 Planned End Date changed from 31 Dec 2023 to 30 Nov 2023.
- 02 Nov 2018 Planned primary completion date changed from 31 Aug 2021 to 31 Jul 2021.
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.